Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Baxter
Moodys
Merck
Express Scripts

Last Updated: November 28, 2022

CLINICAL TRIALS PROFILE FOR EXJADE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Exjade

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00171301 ↗ Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) Completed Novartis Pharmaceuticals Phase 4 2005-06-01 To allow patients treated with deferasirox in the core study to continue iron chelation therapy for 2 years or until the drug became locally commercially available. To evaluate the long-term safety and efficacy of deferasirox by measuring treatment success, change in liver iron content (LIC) and change in serum ferritin levels. Safety was mainly assessed by incidence of adverse events (AEs)and clinically significant lab parameters.
NCT00235391 ↗ Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload Completed Novartis Pharmaceuticals Phase 3 2005-10-01 This is an open-label, non-randomized, multi-center trial designed to provide expanded access of deferasirox to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with locally approved iron chelators.
NCT00419770 ↗ The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study Completed Astellas Pharma Inc Phase 2 2007-10-01 The purpose of this study is to determine if the addition of the medication, deferasirox, to standard antifungal therapy for the infection, mucormycosis, is safe and effective
NCT00419770 ↗ The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study Completed Gilead Sciences Phase 2 2007-10-01 The purpose of this study is to determine if the addition of the medication, deferasirox, to standard antifungal therapy for the infection, mucormycosis, is safe and effective
NCT00419770 ↗ The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study Completed Novartis Phase 2 2007-10-01 The purpose of this study is to determine if the addition of the medication, deferasirox, to standard antifungal therapy for the infection, mucormycosis, is safe and effective
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Exjade

Condition Name

Condition Name for Exjade
Intervention Trials
Myelodysplastic Syndromes 6
Iron Overload 5
Sickle Cell Disease 4
Stage IV Grade 3 Follicular Lymphoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Exjade
Intervention Trials
Iron Overload 16
Preleukemia 12
Myelodysplastic Syndromes 12
Thalassemia 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Exjade

Trials by Country

Trials by Country for Exjade
Location Trials
United States 53
Italy 6
Spain 5
France 4
Germany 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Exjade
Location Trials
California 5
Texas 4
Pennsylvania 4
New York 4
Florida 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Exjade

Clinical Trial Phase

Clinical Trial Phase for Exjade
Clinical Trial Phase Trials
Phase 4 9
Phase 3 4
Phase 2/Phase 3 1
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Exjade
Clinical Trial Phase Trials
Completed 15
Terminated 10
Unknown status 6
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Exjade

Sponsor Name

Sponsor Name for Exjade
Sponsor Trials
Novartis Pharmaceuticals 11
Novartis 7
National Cancer Institute (NCI) 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Exjade
Sponsor Trials
Other 67
Industry 23
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Medtronic
Merck
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.